Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Axsome Therapeutics, Inc.

NASDAQ: AXSM · Life Sciences · 2 alerts · CIK 1579428

Share price
$137.01Close, Nov 16
Market cap
$7.21B
Shares outstanding
52.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Axsome Therapeutics, Inc. filings on SEC EDGAR ↗

4:31 PM ET 10-Q
Financial Results

Axsome Therapeutics Q3 2026 Results: Net Loss of $12.9M, Loss Narrows

Axsome Therapeutics reported total revenues of $259.7 million for the third quarter of 2026, driven primarily by product sales of AUVELITY, SUNOSI, and SYMBRAVO. While the company remains in a net loss position of $12.9 million for the quarter, this represents a significant improvement from the $47.2 million loss in the prior year period as commercial scale increases.

Key figure
Net loss $12.9M
7:06 AM ET 8-K
Financial Results

Axsome Therapeutics Financial Results

Axsome Therapeutics reported Q3 2026 financial results with total net product revenue of $259.7 million, a 52% year-over-year increase driven by strong sales of Auvelity and Sunosi. The company significantly narrowed its net loss to $12.9 million compared to $47.2 million in the prior year period, surpassing a $1 billion annual revenue run rate.

Term
Q3 2026

“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation.”

Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.